ストックスクリーナーアプリを入手
1.80
28.57%
0.40
アフターアワーズ：
1.68
-0.12
-6.67%
前日終値:
$1.40
開ける：
$1.46
24時間の取引高:
34.90M
Relative Volume:
8.69
時価総額：
$166.91M
収益：
-
当期純損益:
$-69.31M
株価収益率:
-1.4173
EPS:
-1.27
ネットキャッシュフロー:
$-62.80M
1週間 パフォーマンス:
-82.73%
1か月 パフォーマンス:
-82.00%
6か月 パフォーマンス:
-59.09%
1年 パフォーマンス:
-61.21%
1日の値動き範囲:
$1.45
$1.85
1週間の範囲:
$1.07
$11.16
52週間の値動き範囲:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
名前
Rezolute Inc
セクター
電話
650-206-4507
住所
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
RZLT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
1.80 | 129.82M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-11 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | ダウングレード | Craig Hallum | Buy → Hold |
| 2025-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-08-27 | 開始されました | Guggenheim | Buy |
| 2024-07-17 | 開始されました | BTIG Research | Buy |
| 2024-06-04 | 開始されました | Craig Hallum | Buy |
| 2024-04-09 | 開始されました | Maxim Group | Buy |
| 2022-08-02 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-09-08 | 開始されました | ROTH Capital | Buy |
| 2021-05-27 | 開始されました | Oppenheimer | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Rezolute Inc (RZLT) 最新ニュース
Rezolute (NASDAQ:RZLT) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Jefferies Raises Rezolute’s Price Target Amid Promising Drug Prospects - StocksToTrade
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView
Jefferies Lifts Rezolute’s Target amid New Data Anticipation - timothysykes.com
Rezolute stock crashes after sole pipeline candidate fails Phase III - Clinical Trials Arena
Craig-Hallum downgrades Rezolute stock to Hold on failed Phase III trial - Investing.com Australia
Rezolute price target lowered to $4 from $20 at Maxim - TipRanks
Rezolute decimated on Phase III miss for ersodetug - The Pharma Letter
Rezolute stock price target slashed by Guggenheim after trial failure - Investing.com Nigeria
RZLT Maintains Buy Rating despite Guggenheim's Lowered Price Tar - GuruFocus
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts - ts2.tech
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire
Craig-Hallum Downgrades Rezolute to Hold From Buy, Adjusts PT to $2 From $18 - marketscreener.com
Rezolute stock price target slashed by H.C. Wainwright after failed study - Investing.com
Rezolute (RZLT): HC Wainwright & Co. Significantly Lowers Price Target | RZLT Stock News - GuruFocus
HC Wainwright & Co. Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
What analysts say about Rezolute Inc 6HV1 stockProtective Put Strategies & Rapid Portfolio Growth - earlytimes.in
Rezolute fails phase 3 for RZ358 as placebo response masks 10 mg/kg efficacyCHOSUNBIZ - Chosunbiz
Rezolute stock hits 52-week low at 1.21 USD despite strong annual gain - Investing.com Canada
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure - The AI Journal
Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Two Biotechs Crash, One Down 88%, On Failed Insulin Drug - Investor's Business Daily
Rezolute, Inc. (RZLT): The "sunRIZE" Post-Mortem & The Tumor Hyperinsulinism Pivot (NASDAQ:RZLT) - Seeking Alpha
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns - ts2.tech
Rezolute (RZLT): Assessing Valuation After a Year of Strong Share Price Gains - Yahoo Finance
Is RZLT Stock A Hidden Gem? - StocksToTrade
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - The AI Journal
Rezolute, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – RZLT - marketscreener.com
Market movers: Rezolute, Oracle, Planet Labs… - Proactive Investors
Failed Trials And Missed Targets Send Shares Reeling - Finimize
Rezolute (RZLT) Stock: Dips Sharply After Phase 3 SunRIZE Trial Disappoints Investors - parameter.io
Rezolute stock price target cut to $5 from $17 at BTIG after trial failure - Investing.com
RZLT: Phase 3 Sunrise study for ersodetug in congenital HI failed to show significant benefit over placebo - TradingView
Rezolute plunges 90% as Phase 3 sunRIZE trial for low BP fails | Tap to know more | Inshorts - Inshorts
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage - ts2.tech
Rezolute keeps door open for hyperinsulinism drug despite Phase III miss - FirstWord Pharma
Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial - Benzinga
Rezolute’s lone drug misses a phase III - BioWorld MedTech
Rezolute (RZLT) Shares Plummet 89% After Phase 3 Trial Setback - GuruFocus
INVESTOR ALERT: Investigation of Rezolute, Inc. (RZLT) by Holzer & Holzer, LLC - GlobeNewswire
Rezolute (RZLT) Downgraded by Wedbush Following Phase 3 Study Re - GuruFocus
Rezolute Downgraded to Hold Amid Disappointing Phase 3 Trial Results for Ersodetug - TipRanks
Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss - TipRanks
Is Rezolute (RZLT) Using sunRIZE Phase 3 And Shelf Filing To Quietly Recast Its Strategy? - simplywall.st
BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities - GlobeNewswire
Wedbush Downgrades Rezolute to Neutral From Outperform, Price Target is $1 - marketscreener.com
Rezolute (RZLT) Shares Dip Following Phase 3 Trial Setback - GuruFocus
Rezolute (RZLT) Shares Tumble Following Phase 3 Study Results - GuruFocus
Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test - Fierce Biotech
Rezolute Inc (RZLT) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):